Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
ADVANCED SOLID TUMORS: PHASE 1: ADENOSINE PATHWAY: TTX-030-002

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors

Title
Tizona TTX-030-002 (TTX-030 + budigalimab)
Study Title

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors

Site Link
Malignancy
Prostate, Kidney, Head and Neck, Colon Rectum, Gastric, Esophagus
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
late line
Investigational Agent
TTX-030, budigalimab
Drug Class
Anti CD-39, anti-PD1
PI
Dan Vaena, MD
Sponsor
Tizona Therapeutics
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Advanced Solid Malignancy
  • Fresh and/or archival tumor tissue
  • Evidence of measurable disease (except for prostate)
  • Life expectancy >12 weeks
  • ECOG PS 0-1
  • No therapeutic anticoagulation
  • no history of autoimmune disease
  • No uncontrolled intercurrent illness
  • No HTN >150/90 despite optimal management
  • No active CNS mets
  • No other malignancies within 3 years
  • No autoimmune toxicity >Grade 3 from prior immunotherapy
Objective
  • Primary
    • Adverse Events
  • Secondary
    • ORR
    • DoR
    • DCR
    • PFS
    • PK
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Any
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
X